πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,432 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10981915

Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors

Valo Early Discovery, Inc. Β· Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10981906

Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same

Aclaris Therapeutics, Inc. Β· Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10981896

Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase

The Board of Regents of the University of Texas System Β· Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10980889

C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors

Revolution Medicines, Inc. Β· Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10980797

Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors

Corcept Therapeutics Incorporated Β· Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10980793

Methods of treating cancer with farnesyltransferase inhibitors

Kura Oncology, Inc. Β· Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10975167

Method to reduce pulmonary arterial hypertension by administering inhibitors of nicotinami

Arizona Board of Regents on Behalf of the University of Arizona Β· Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10973830

Substituted quinoxaline DNA-PK inhibitors

Vertex Pharmaceuticals Incorporated Β· Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10975094

Heterocyclic compounds as RSV inhibitors

Enanta Pharmaceuticals, Inc. Β· Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10968205

Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10968180

Piperidine derivatives as HDAC1/2 inhibitors

Regenacy Pharmaceuticals, Inc. Β· Granted Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10968178

IP6K inhibitors

Takeda Pharmaceutical Company Limited Β· Granted Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10961200

Small molecule inhibitors of lactate dehydrogenase and methods of use thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Mar 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10959984

Methods for treating cancer with RORΞ³ inhibitors

The Regents of the University of California Β· Granted Tue Mar 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10961232

Substituted pyrazines as ATR kinase inhibitors

Vertex Pharmaceuticals Incorporated Β· Granted Tue Mar 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10954237

JAK inhibitors containing a 4-membered heterocyclic amide

Theravance Biopharma R&D IP, LLC Β· Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10954228

1 H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use there

NATIONAL INSTITUTES OF HEALTH, UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES Β· Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10952997

Methods for the administration of certain VMAT2 inhibitors

Neurocrine Biosciences, Inc. Β· Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10952996

ALK5 inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10947238

Wee1 kinase inhibitors and methods of making and using the same

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10941183

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bow

Protagonist Therapeutics, Inc. Β· Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10941140

IRAK inhibitors and method for making and using

Rigel Pharmaceuticals, Inc. Β· Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10940141

Methods for the administration of certain VMAT2 inhibitors

Neurocrine Biosciences, Inc. Β· Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10934332

Structure-based peptide inhibitors that target the Tau VQIINK fibrillization segment

The Regents of the University of California Β· Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted